Archived Insight | March 30, 2020

New York Times Article on Coronavirus and Health Insurance

Segal's Ed Kaplan was included in an in-depth article in The New York Times examining the predicted effect of the coronavirus on health insurance premiums.

Read the article.

Questions about the subject of this article?

Talk to one of our consultants to get the answers you need.

What you'll find in this article

The article discusses how the pandemic has caught insurers and health plans unawares, which could lead to a huge increase in premiums next year. Some of the factors that will determine the fate of premiums include the scope of the pandemic in America, how much it costs to treat COVID-19 patients, and how much financial relief the government will provide.

Learn more from Segal

Hispanic Male At A Doctors Appointment With A Black Female Doctor Checking Blood Pressure

Reasons to Consider an On-Site or Near-Site Clinic

On‑site and near‑site clinics can reduce costs, improve access and experience, and deliver ROI while strengthening health and wellness programs.

Health, Multiemployer Plans, Public Sector, Healthcare Industry, Higher Education, Architecture Engineering & Construction, Corporate, Healthcare Cost Management

Read Full Insight

Black Male And Caucasian Female Pharmacists Working At The Pharmacy

Rx Claims Audit Recovers Millions for Employer Coalition

An employer coalition revealed pharmacy benefit manager (PBM) pricing errors through an independent pharmacy claims audit, recovering $5.5 million.

Pharmaceutical, Health, Benefits Administration, Benefit Audit Solutions

Read Full Insight

Asia Female Pharmacist Using Digital Tablet While Taking Inventory

New Requirements for PBM Reporting and Fee Disclosures

The Consolidated Appropriations Act of 2026 makes significant reforms to pharmacy benefit manager practices. See the impact on health plan sponsors.

Compliance, Health, Multiemployer Plans, Public Sector, Healthcare Industry, Higher Education, Architecture Engineering & Construction, Corporate, Pharmaceutical

Read Full Insight

Explore all COVID-19 information

We're regularly publishing information on the coronavirus as the situation changes.

Learn More

This page is for informational purposes only and does not constitute legal, tax or investment advice. You are encouraged to discuss the issues raised here with your legal, tax and other advisors before determining how the issues apply to your specific situations.